stockrow
Friday 6 November 2026
Export ARAY’s income statement to Excel — free account
Accuray Incorporated
ARAY Healthcare Medical Devices
Accuray Incorporated’s revenue for fiscal 2026 (year ended June 2026) was $401.9 million, down 12.3% from fiscal 2025.
- Revenue
- −7.90%
- EPS
- +138.9%
- Free cash flow
- −138.3%
- Total debt
- −25.4%
Quarter to September 2026, against a year earlier
0.11
0.01
−8.33%
Follow ARAY
Alert me
| Sep '26 From the 10-Q filed 6 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.09 | 0.08 | 0.11 | 0.23 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.79) | 13.14 | (8.65) | (6.21) | |
P/B ratio |
0.70 | 0.76 | 1.16 | 1.86 | |
Price to Tangible BV |
1.22 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.23 | 0.34 | 0.34 | 0.42 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.96) | (19.63) | (7.53) | 40.05 | |
EV/FCF |
(3.36) | (10.61) | (5.56) | (66.78) | |
Quick Ratio |
0.00 | 0.57 | 0.50 | 0.52 | |
Current Ratio |
1.56 | 1.50 | 1.42 | 1.47 | |
Net Debt/EBITDA |
(3.19) | 10.74 | (20.39) | (10.65) | |
Debt/Assets |
24.35% | 32.99% | 29.94% | 27.85% | |
Debt/Equity |
1.79 | 3.51 | 3.21 | 2.34 | |
Asset Turnover |
0.93 | 0.88 | 0.92 | 0.94 | |
Operating CF/Net income |
(0.38) | (1.25) | 0.47 | 1.16 | |
Capex/Depreciation |
(0.02) | (0.11) | (0.11) | (0.80) | |
Interest Coverage |
(3.09) | 0.64 | (1.08) | (1.50) | |
Research and Development Expense of Revenue |
0.00% | 7.49% | 7.80% | 10.42% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 18.73% | 18.76% | 18.50% | |
Intangible Assets out of Total Assets |
0.06 | 0.13 | 0.13 | 0.13 | |
Share Based Compensation of Revenue |
1.30% | 1.66% | 1.31% | 0.86% | |
Graham Net Nets |
(1.90) | (3.58) | (2.32) | (1.03) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(55.56%) | (153.85%) | (94.87%) | (35.37%) | |
Free Cash Flow Yield |
(72.68%) | (40.49%) | (53.43%) | (2.75%) | |
Revenue per Share |
0.63 | 0.82 | 0.84 | 0.85 | |
Operating CF per Share |
(0.03) | 0.02 | (0.05) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Free Cash Flow per Share |
(0.03) | 0.02 | (0.05) | (0.16) | |
Cash per Share |
0.00 | 0.34 | 0.31 | 0.35 | |
Shareholders Equity per Share |
0.38 | 0.34 | 0.34 | 0.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.38 | 0.34 | 0.34 | 0.44 | |
Free Cash Flow |
(3.94) | 1.97 | (6.07) | (19.01) | |
Working Capital |
95.94 | 96.37 | 87.37 | 92.95 | |
Capital Expenditures |
(0.12) | (0.46) | (0.47) | (3.02) | |
Net Current Asset Value |
(70.89) | (114.20) | (112.68) | (102.20) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 75.30 | 71.38 | 74.12 | |
Average Payables |
37.73 | 37.29 | 49.56 | 48.76 | |
Average Inventory |
150.79 | 144.05 | 151.54 | 149.89 | |
Average Assets |
423.44 | 456.96 | 465.95 | 463.20 | |
Average Common Equity |
57.49 | 61.43 | 45.65 | 50.66 |
Columns are period end dates · fundamentals updated 6 Nov 2026